Enfortumab vedotin: tested in a combination
34 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingNCT07908979Phase 2Report a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2Report a problem
- A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingNCT07822373Phase 2Report a problem
- Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingNCT07663747Phase 2Report a problem
- EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBCRecruitingNCT07647289Phase 2Report a problem
- Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingNCT07643519Phase 2Report a problem
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3Report a problem
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2Report a problem
- The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder CancerNot yet recruitingNCT07346053Phase 3Report a problem
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2Report a problem
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1Report a problem
- Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2Report a problem
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingNCT07110038Phase 2Report a problem
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2Report a problem
- Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2Report a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2Report a problem
- Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2Report a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2Report a problem
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingNCT06041503Phase 2Report a problem
- Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2Report a problem
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2Report a problem
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2Report a problem
- Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2Report a problem
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingNCT04724018Phase 1/2Report a problem
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT04223856Phase 3Results postedReport a problem
- Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active, not recruitingNCT03924895Phase 3Results postedReport a problem
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results postedReport a problem
- PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2Report a problem
- A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)Active, not recruitingNCT06483334Phase 1/2Report a problem
- Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2Report a problem
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2Report a problem
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1Report a problem
- Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3Report a problem
- Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3Report a problem